Candel Therapeutics, Inc. (CADL) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Candel Therapeutics, Inc. (CADL) Healthcare & Pipeline Overview

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in immunotherapies for cancer, with a robust pipeline that includes CAN-2409 and CAN-3110, targeting various malignancies and positioning itself as a key player in the oncology treatment landscape.

What Is the Investment Thesis for CADL?

With CAN-2409 progressing through multiple clinical trials, the company is positioned to capture significant market share in the oncology sector, particularly in pancreatic and prostate cancers, which represent substantial unmet medical needs. The global cancer immunotherapy market is projected to reach $100 billion by 2026, providing a robust backdrop for Candel's growth. Additionally, the successful completion of clinical trials and subsequent regulatory approvals could lead to lucrative partnerships or acquisitions, enhancing shareholder value. However, investors should remain cognizant of the inherent risks associated with clinical-stage biopharmaceutical companies, including trial outcomes and regulatory hurdles.

Based on FMP financials and quantitative analysis

CADL Key Highlights

Market Cap of $765M reflects investor interest in innovative cancer therapies.

• Phase II/III trials for CAN-2409 indicate strong potential in addressing critical cancer types.
• No dividend yield as the company reinvests in research and development.
• Beta of -0.81 suggests lower volatility compared to the market, appealing to risk-averse investors.
• Small workforce of 38 employees allows for agile decision-making and focused development efforts.

Who Are CADL's Competitors?

CADL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CADL's Key Strengths?

Innovative drug pipeline with multiple candidates in clinical trials.

• Strong focus on immunotherapy, a rapidly growing segment in oncology.
• Experienced leadership team with expertise in biopharmaceuticals.
• Small team allows for agile decision-making and focused development.

What Are CADL's Weaknesses?

Limited financial resources compared to larger competitors.

• Dependence on the success of clinical trials for future growth.
• No current revenue streams as the company is in clinical stages.
• Small workforce may limit operational capacity and scalability.

What Could Drive CADL Stock Higher?

CADL catalyst: Results from Phase II clinical trials for CAN-2409 expected in late 2026, which could validate its efficacy in pancreatic cancer.

• Phase III clinical trials for CAN-2409 in prostate cancer, with potential for significant market impact.
• Initiation of Phase I trials for CAN-3110, targeting recurrent glioblastoma, anticipated in mid-2026.
• Continuous engagement with regulatory bodies to facilitate timely approvals for its therapies.
• Potential strategic partnerships with larger biopharmaceutical firms to enhance development capabilities.

What Are the Key Risks for CADL?

Negative return on equity (-60.4%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures could delay or derail product development timelines.
• Regulatory hurdles may impact the approval process for new therapies.
• Market competition from established players could limit Candel's market share.
• Dependence on external funding sources for operational sustainability.

What Are the Growth Opportunities for CADL?

• Expansion of CAN-2409: Candel Therapeutics is advancing CAN-2409 through multiple clinical trials, targeting pancreatic, prostate, and lung cancers. The global market for pancreatic cancer therapeutics is expected to grow to $4.5 billion by 2026, presenting a significant opportunity for Candel if the trials yield positive results.
• Successful development could position Candel as a leader in this challenging therapeutic area.
• Strategic partnerships: Candel may seek collaborations with larger biopharmaceutical companies to leverage their resources and distribution networks, enhancing the commercial potential of its therapies. This could lead to accelerated development timelines and increased market reach.
• Regulatory approvals: Achieving FDA and EMA approvals for its therapies could unlock significant revenue streams and enhance Candel's credibility in the market. The timeline for potential approvals could align with the projected growth of the cancer therapy market, providing a timely opportunity.
• Geographic expansion: Candel Therapeutics has the potential to expand its market presence internationally, particularly in emerging markets where cancer treatment options are limited. This could significantly increase its addressable market and revenue potential.

What Threats Does CADL Face?

• Intense competition from larger biopharmaceutical companies.
• Regulatory challenges and potential delays in clinical trial approvals.
• Market volatility affecting funding and investor sentiment.
• Rapid advancements in cancer treatment could outpace Candel's development.

What Are CADL's Competitive Advantages?

• Innovative pipeline of immunotherapies targeting high unmet needs in oncology.
• Strong focus on clinical trials, enhancing the likelihood of successful product development.
• Experienced leadership team with a track record in biopharmaceutical development.
• Potential for strategic partnerships that can enhance market reach and resource access.
• Niche focus on specific cancer types may provide a competitive edge against larger players.

What Does CADL Do?

Candel Therapeutics, Inc., founded in 2003 and headquartered in Needham, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing immunotherapies for cancer patients. Originally known as Advantagene, Inc., the company rebranded in November 2020 to reflect its focus on innovative therapeutic solutions. Candel's lead product candidate, CAN-2409, is currently undergoing Phase II clinical trials for pancreatic cancer, Phase III trials for prostate cancer, and Phase II trials for lung cancer. Additionally, CAN-2409 has completed Phase Ib/II trials for high-grade glioma, showcasing its potential across multiple cancer types. The company is also advancing CAN-3110, which is in Phase I trials for recurrent glioblastoma. With a small but dedicated team of 38 employees, Candel Therapeutics aims to leverage its expertise in immunotherapy to address significant unmet needs in oncology, positioning itself as a forward-thinking entity in the biopharmaceutical landscape.

What Products and Services Does CADL Offer?

• Develops immunotherapies specifically targeting various types of cancer.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Focuses on innovative treatment options for patients with high unmet medical needs.
• Operates primarily in the oncology sector, addressing multiple cancer types.
• Engages in research and development to advance its therapeutic pipeline.
• Seeks partnerships and collaborations to enhance drug development and market reach.

How Does CADL Make Money?

• Generates revenue through the development and commercialization of cancer therapies.
• Secures funding through equity financing and potential partnerships with larger biopharmaceutical companies.
• Invests in research and development to advance its clinical pipeline and bring new therapies to market.
• May receive milestone payments and royalties from partnerships upon successful drug approvals.
• Focuses on creating value through innovative therapies that address significant healthcare needs.

What Industry Does CADL Operate In?

The biotechnology industry, particularly in the oncology sector, is experiencing rapid growth driven by advancements in immunotherapy and personalized medicine. The global cancer immunotherapy market is expected to grow at a CAGR of 15% from 2021 to 2026, reaching approximately $100 billion. Candel Therapeutics, with its focus on immunotherapies, is well-positioned to capitalize on this trend. The competitive landscape includes established players like Bristol-Myers Squibb and Merck, but Candel's targeted approach to specific cancer types may provide a unique advantage in niche markets.

Who Are CADL's Key Customers?

• Primarily targets healthcare providers and oncologists who treat cancer patients.
• Engages with hospitals and cancer treatment centers for clinical trial participation.
• Collaborates with pharmaceutical companies for potential partnerships and licensing agreements.
• Focuses on patients suffering from various types of cancer, particularly those with limited treatment options.
• Works with regulatory bodies to ensure compliance and approval of its therapies.

Company Profile

Candel Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Needham, United States.

How Candel Therapeutics, Inc. Is Valued

Candel Therapeutics, Inc. carries a market capitalization of $765M, placing it in the small-cap category. Analyst price targets span from $22.00 to $23.00, with a consensus of $22.50. At the current price of $10.44, that implies approximately 115% upside potential. Relative to its peer group, CADL's quantitative score of 56/100 is below the peer average of 86/100.

Return on equity for Candel Therapeutics, Inc. stands at -60.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -27.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -8.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 28.05 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -8.5%, the inverse of the P/E and a quick read on earnings relative to price.

Candel Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 4.43 places it in the safe zone, indicating low near-term bankruptcy risk.

Candel Therapeutics, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 30.1% below estimates on average.

Wall Street analysts project Candel Therapeutics, Inc. revenue of about $92.5M for fiscal 2026, with EPS near $-1.30. The estimate reflects 7 contributing analysts.

Over the past six months, Candel Therapeutics, Inc. insiders filed 19 SEC Form 4 transactions — 3 sales and 16 purchases. On net that is roughly 548K shares acquired (about $5.2M) — insiders putting money in tends to read as conviction.

CADL Financials

CADL Latest News

CADL Analyst Consensus

CADL MoonshotScore

Common Questions About CADL (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources